



**The Liver Meeting
53rd Annual Meeting of The American Association for the
Study of Liver Diseases**

November 1 - 5, 2002

**John B. Hynes Convention Center
Boston, Massachusetts**

Annual Meeting Description Courses and Sessions

Plenary and Parallel Session Schedule

Poster Session Schedule

Postgraduate Course

PG Meet-the-Professor Luncheons

General Hepatology Update

State-of-the-Art Lectures

Research Workshop

Hepatology Associates Course

AASLD/ILTS Transplant Course

Transplant Meet-the-Professors Luncheons

AASLD/NASPGHAN Pediatric Symposium

AASLD/AHPBA Surgical Forum

Early Morning Workshops

**AASLD/ALF Report Back on NIH Consensus Conference on the
Management of Hepatitis C**

Friday, November 1st, 2002

AASLD/ILTS Liver Transplant Course

Liver Transplantation for Viral Hepatitis

8:00 a.m. - 3:00 p.m.

Course Directors: Anna S.F. Lok, MD; Sue V. McDiarmid, MD; Federico G. Villamil, MD
6 CME Credits

Goals and Objectives:

Review the natural history of recurrent hepatitis B and C post-liver transplant.

Gain insight into the factors associated with recurrent hepatitis B and C and pathogenesis of recurrent hepatitis C.

Understand the impact of immunosuppressive therapy on the course of recurrent hepatitis C.

Discuss options for preventing recurrent hepatitis B and C.

Review treatment of recurrent hepatitis B and C.

Discuss the pros and cons of re-transplantation and the use of anti-HBc positive donor liver.

Hepatitis C is the most common indication for liver transplantation in western countries. Unfortunately, HCV reinfection is universal after liver transplantation. Moreover, the natural history of recurrent hepatitis C is accelerated. Thus, physicians involved in the care of liver transplant patients must have a clear understanding of the pathogenesis of recurrent hepatitis C, and the impact of immunosuppressive therapy on the course of these patients. Antiviral therapy has been used to prevent or treat recurrent hepatitis C but tolerance is poor in post-transplant patients.

Physicians managing these patients need to be aware of the problems that are unique to the transplant population. Significant progress has been made in the past 15 years on the prevention of recurrent hepatitis B post-liver transplant. The outcome of patients transplanted for hepatitis B is better than that of patients transplanted for hepatitis C, but current prophylactic regimens for recurrent hepatitis B are very expensive.

Optimal use of nucleos(t)ide analogs can improve the cost-effectiveness of prophylactic therapies for recurrent hepatitis B and the outcome of patients with recurrent hepatitis B.

8:00 a.m. - 8:05 a.m.

Introduction

Sue V. McDiarmid, MD

Session I - Hepatitis C

Chairs: Michael F. Sorrell, MD and Federico G. Villamil, MD

8:05 a.m. - 8:15 a.m.

Magnitude of the Problem

Jorge L. Rakela, MD

8:15 a.m. - 8:35 a.m.

Pathogenesis of Recurrent Hepatitis C

Geoffrey W. McCaughan, MD

8:35 a.m. - 8:55 a.m.

Natural History of Recurrent Hepatitis C
Marina Berenguer, MD

8:55 a.m. - 9:15 a.m.

Impact of Immunosuppressive Therapy
Gregory T. Everson, MD

9:15 a.m. - 9:45 a.m.

Discussion

9:45 a.m. - 10:05 a.m.

Break

Session II -- Hepatitis C

Chairs: Peter Neuhaus, MD and Hugo R. Rosen, MD

10:05 a.m. - 10:25 a.m.

Treatment of Recurrent Hepatitis C
Edward J. Gane, MD

10:25 a.m. - 10:35 a.m.

Re-Transplantation for Recurrent Hepatitis C
Rafik M. Ghobrial, MD, PhD

10:35 a.m. - 10:45 a.m.

Discussion

Debate I: Immunosuppression in Hepatitis C

Chairs: Peter Neuhaus, MD and Hugo R. Rosen, MD

10:45 a.m. - 10:52 a.m.

I Favor Induction Immunosuppression
Michael R. Lucey, MD

10:52 a.m. - 10:59 a.m.

I Do Not Favor Induction Immunosuppression
Andrew K. Burroughs, MD

10:59 a.m. - 11:05 a.m.

Rebuttals

Debate II: Therapy of Recurrent Hepatitis C
Chairs: Peter Neuhaus, MD and Hugo R. Rosen, MD

11:05 a.m. - 11:12 a.m.

Pre-Emptive/Treatment of Recurrent Hepatitis
Michael R. Charlton, MD

11:12 a.m. - 11:19 a.m.

I Favor Therapy Following Recurrence
Didier Samuel, MD

11:19 a.m. - 11:25 a.m.

Rebuttals

11:25 a.m. - 11:45 a.m.

Discussion

AASLD/ILTS Transplant Course Meet-the-Professor Luncheons

11:45 a.m. - 1:00 p.m.
1 CME Credit

- ❖ Antiviral Therapy in Patients Awaiting Liver Transplantation for Hepatitis C: Is this Feasible?
Gregory T. Everson, MD and Jorge L. Rakela, MD
- ❖ Assessment of Recurrent Hepatitis C: Are Protocol Biopsies Necessary? How Reliable are Biopsies in Predicting Long-Term Outcome?
Marina Berenguer, MD and Anthony Demetris, MD
- ❖ Pathogenesis of Liver Damage in Recurrent HCV Infection: Is it the Virus, the Host or Immunosuppression?
Geoffrey W, McCaughan, PhD, MBBS and Hugo R. Rosen, MD
- ❖ Immunosuppressive Therapy for Patients Transplanted for Hepatitis C: What is the

Optimal Regimen for Prevention and Treatment of Rejection?
Andrew K. Burroughs, MD and John J. Fung, MD, PhD

- ❖ Antiviral Therapy in Patients Transplanted for Hepatitis C: When Should this be Initiated and What is the Ideal Regimen?
Michael R. Charlton, MD and Peter Ferenci, MD, PhD
- ❖ Optimal Use of Lamivudine Before and After Liver Transplantation. When Should Lamivudine be Initiated in Patients Awaiting Liver Transplantation?
Robert G. Gish, MD and Eugene R. Schiff, MD
- ❖ Lamivudine Resistant Mutations Before or After Liver Transplantation for Hepatitis B: How Should These Patients be Managed?
Robert P. Perrillo, MD and Robert J. Fontana, MD
- ❖ HBV Prophylaxis for Patients Transplanted for Hepatitis B: How Much is Needed in the Era of Antiviral Therapy?
Didier Samuel, MD and Anna S.F. Lok, MD
- ❖ Role of Hepatitis B Vaccination in Preventing de Novo and Recurrent HBV Infection. Can Vaccines Replace HBIG?
Mario Angelico, MD and Juan Rodes, MD
- ❖ What is the Most Cost-Effective Regimen to Prevent Recurrent HBV Infection Following Liver Transplantation?
Timothy L. Pruett, MD and Norah Terrault, MD, MPH
- ❖ Liver Transplantation for Viral Hepatitis in Children
Sue V. McDiarmid, MD and John C. Bucuvalas, MD, PhD
- ❖ Liver Transplantation for HCC: How Far We Can Push the Envelope?
John R. Lake, MD and Ronald W. Busuttil, MD, PhD
- ❖ Which Patients Should Receive Livers from Anti-HBc (+) Donors? What is the Optimal Prophylactic Therapy?
Santiago J. Munoz, MD and Martin Prieto, MD
- ❖ Re-Transplantation for Hepatitis C: Should This be Performed?
Michael R. Lucey, MD and Byers W. Shaw, MD
- ❖ Living-Donor Liver Transplantation for Patients with Hepatitis B or C: What Can Be Done to Donors and Recipients Prior to Transplantation to Reduce the Risk of Re-infection?
James F. Trotter, MD and Charles Miller, MD

1:10p.m. – 3:00p.m.

Session III - Hepatitis B

Chairs: Anna S.F. Lok, MD and Juan Rodes, MD

1:10 p.m. - 1:20 p.m.

Progress in the Last 15 Years
Federico G. Villamil, MD

1:20 p.m. - 1:40 p.m.

Prevention of Recurrent Hepatitis B
Anna S.F. Lok, MD

1:40 p.m. - 2:00 p.m.

Treatment of Recurrent Hepatitis B
Norah Terrault, MD,MPH

2:00 p.m. - 2:10 p.m.

Use of Anti-HBc (+) Donors
Santiago J. Munoz, MD

Debate III: Hepatitis B Immunoglobulin

Chairs: Anna S.F. Lok, MD and Juan Rodes, MD

2:10 p.m. - 2:17 p.m.

I Favor Indefinite Therapy
Timothy L. Pruett, MD

2:17 p.m. - 2:24 p.m.

I Favor Limited Duration of Therapy
John R. Lake, MD

2:24 p.m. - 2:30 p.m.

Rebuttals

2:30 p.m. - 3:00 p.m.

Discussion

3:00 p.m.

Adjourn

Supported, in part, by an unrestricted educational grant from Fujisawa Healthcare, Inc.

AASLD/NASPGHAN Pediatric Symposium

Recent Advances in Neonatal Cholestasis

Course Directors: James E. Heubi, MD and Saul J. Karpen, MD, PhD

12:00 p.m. - 3:00 p.m.

3 CME Credits

Goals and Objectives:

Define current and future strategies for diagnosis and treatment of medical and surgical causes of neonatal cholestasis.

Delineate current understanding of Alagille Syndrome, PFIC, and the potential role of nuclear receptors in the pathogenesis of neonatal cholestasis.

Discuss controversies in surgical and medical management, and the evolving role of molecular genetics in our understanding of the pathogenesis of neonatal cholestasis.

Neonatal cholestasis is the presenting sign for a group of diseases which continue to present a diagnostic challenge to the clinician. Over the last decade, significant advances have been made in our understanding of the causes and treatment of diseases such as biliary atresia, Alagille Syndrome, PFIC and others. This symposium will focus on current approaches to the diagnosis and management of conditions presenting with neonatal cholestasis, for which better understanding of pathogenesis and the role of genetics have been realized in recent years.

12:00 p.m. - 12:10 p.m.

Overview/Aims

James E. Heubi, MD

12:10 p.m. - 12:30 p.m.

Diagnostic Strategies

Benjamin L. Shneider, MD

12:30 p.m. - 12:50 p.m.

Surgical Causes of Neonatal Cholestasis

Stephen Dunn, MD

12:50 p.m. - 1:10 p.m.

Biliary Atresia
Jorge A. Bezerra, MD

1:10 p.m. - 1:20 p.m.

Controversies in Diagnosis and Surgical Management of Cholestatic Liver Disease
Benjamin L. Shneider, MD; Stephen Dunn, MD; and Jorge A. Bezerra, MD

1:20 p.m. - 1:30 p.m.

Break

1:30 p.m. - 1:50 p.m.

Alagille's Syndrome
David Piccoli, MD

1:50 p.m. - 2:10 p.m.

Progressive Familial Intrahepatic Cholestasis
Emmanuel Jacquemin, MD, PhD

2:10 p.m. - 2:30 p.m.

Role of Nuclear Factors in Neonatal Cholestasis
Saul J. Karpen, MD, PhD

2:30 p.m. - 2:50 p.m.

Medical/Surgical Treatment (including OLTx) of Neonatal Cholestasis
Estella M. Alonso, MD

2:50 p.m. - 3:00 p.m.

Controversies in Intrahepatic Cholestasis
David Piccoli, MD; Emmanuel Jacquemin, MD, PhD; and Estella M. Alonso, MD

Postgraduate Course

Mechanisms of Acute and Chronic Liver Diseases: Implications for Diagnosis,
Pathogenesis and Treatment
Course Directors: Frederick J. Suchy, MD; J. Gregory Fitz, MD; and Jacquelyn J. Maher,
MD

4:00 p.m. - 8:00 p.m.

11.5 CME Credits

Goals and Objectives:

Provide the attendees with the most current information on inherited and acquired cholestatic disorders, including their pathophysiology and approaches to diagnosis and treatment.

Gain an understanding of the mechanisms underlying fatty liver disease, including non-alcoholic steatohepatitis and alcoholic liver disease.

Current strategies for diagnosis and treatment will be reviewed.

Learn recent advances in the diagnosis and treatment of the most important inborn errors in metabolism affecting the liver. There will be a particular emphasis on primary hemochromatosis and Wilson's disease.

4:00 p.m. - 4:10 p.m.

Welcome and Introduction
Frederick J. Suchy, MD

Session I: Inherited and Acquired Cholestatic Disorders

4:10 p.m. - 4:30 p.m.

Molecular Mechanisms of Bile Formation and Cholestasis
James L. Boyer, MD

4:30 p.m. - 4:50 p.m.

Cholangiocyte Biology and Pathobiology
J. Gregory Fitz, MD

4:50 p.m. - 5:10 p.m.

Alagille Syndrome: The Jagged 1 Gene and its Receptor
Nancy Spinner, PhD

5:10 p.m. - 5:30 p.m.

Progressive Familial Intrahepatic Cholestasis: Correlation of Genotype with Phenotype
Emmanuel Jacquemin, MD, PhD

5:30 p.m. - 5:50 p.m.

Primary Biliary Cirrhosis: New Concepts Beyond the AMA
Eric M. Gershwin, MD

5:50 p.m. - 6:00 p.m.

Discussion and Questions

6:00 p.m. - 6:20 p.m.

Break

6:20 p.m. - 6:40 p.m.

Primary Biliary Cirrhosis: An Update on Clinical Features and Treatment Options
E. Jenny Heathcote, MD

6:40 p.m. - 7:00 p.m.

Primary Sclerosing Cholangitis: Diagnosis and Treatment
Keith D. Lindor, MD

7:00 p.m. - 7:20 p.m.

Diagnosis and Treatment of Cholangiocarcinoma
Gregory J. Gores, MD

7:20 p.m. - 7:40 p.m.

Drug-induced Liver Disease and Cholestasis
Neil Kaplowitz, MD

7:40 p.m. - 8:00 p.m.

Controversies in Treatment of Pruritus: Rifampin vs. Opioid Receptor Antagonists
E. Jenny Heathcote, MD vs. Nora V. Bergasa, MD

Saturday, November 2nd, 2002

Postgraduate Course

8:00a.m. – 4:45p.m.

Session II: Fatty Liver Disease: Epidemic of the New Millennium

8:00 a.m. - 8:20 a.m.

Mechanisms of Steatohepatitis: From Mice to Men
Anna Mae Diehl, MD

8:20 a.m. - 8:40 a.m.

Mitochondrial Injury in Steatohepatitis
Dominique Pessayre, MD

8:40 a.m. - 9:00 a.m.

Alcoholic Liver Disease: New Concepts in Pathogenesis
David W. Crabb, MD

9:00 a.m. - 9:20 a.m.

Management of Alcoholic Liver Disease from Steroids to Transplantation
Craig McClain, MD

9:20 a.m. - 9:40 a.m.

What Causes Fibrosis in Steatosis?
Scott L. Friedman, MD

9:40 a.m. - 10:10 a.m.

Break

10:10 a.m. - 10:30 a.m.

Role of Pathology in Management of Fatty Liver Disease
Zachary D. Goodman, MD, PhD

10:30 a.m. - 10:50 a.m.

Insulin Resistances, Obesity, and Fatty Liver Disease
Arthur J. McCullough, MD

10:50 a.m. - 11:10 a.m.

Evaluation and Management of Non-Alcoholic Fatty Liver Disease (NAFLD)
Arun Sanyal, MD

11:10 a.m. - 11:30 a.m.

Disorders of Fatty Acid Oxidation: Implications for Disease in Children and Their Mothers
Piero Rinaldo, MD, PhD

11:30 a.m. - 11:50 a.m.

Treatment of Alcoholic Liver Disease: Steroids vs. No Steroids
Craig McClain, MD vs. Robert L. Carithers, Jr., MD

Postgraduate Course Meet-the-Professor Luncheons

12:00 p.m. - 1:30 p.m.

1.5 CME Credits

The goal of the Meet-the-Professor Luncheons is to provide the attendees with an opportunity to explore in more detail a wide variety of topics in hepatology in a small group setting. Moderators are experts in their particular specialty area for a given session.

- ❖ Therapy of Hepatitis C
Eugene R. Schiff, MD and Raymond S. Koff, MD
- ❖ Fulminant Hepatic Failure
William M. Lee, MD and Robert J. Fontana, MD
- ❖ Iron and Hepatitis C
Bruce R. Bacon, MD and Herbert L. Bonkovsky, MD
- ❖ Recent Advances in Neonatal Cholestasis
Benjamin L. Shneider, MD and William F. Balistreri, MD
- ❖ Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)
Laurie D. DeLeve, MD, PhD and George B. McDonald, MD
- ❖ HCV in African Americans and Other Minorities
John G. McHutchison, MD and Lennox Jeffers, MD, FACP
- ❖ Management of Ascites and its Complications
Bruce A. Runyon, MD and Guadalupe Garcia-Tsao, MD
- ❖ Treatment Options for Hepatocellular Carcinoma
C. Wright Pinson, MD, MBA and J. Michael Henderson, MD
- ❖ Advances in Hepatocyte Transplantation
Ira J. Fox, MD and Jayanta Roy Chowdhury, MD
- ❖ Pharmacogenetics and Drug-Induced Liver Disease
Paul B. Watkins, MD and Christopher P. Day, MD, PhD
- ❖ Obesity and Hepatitis C
Zobair M. Younossi, MD, MPH and Thelma E. Wiley, MD

- ❖ Therapy of Hepatitis B**
Robert P. Perrillo, MD and Jules L. Dienstag, MD
- ❖ Hepatitis B Mutants: Clinical Importance**
Jake T. Liang, MD and Anna S.F. Lok, MD
- ❖ Natural History of Hepatitis C
Leonard B. Seeff, MD and Norah Terrault, MD, MPH
- ❖ Prognosis in Chronic Liver Disease
Patrick S. Kamath, MD and Michael R. Lucey, MD
- ❖ Cytokines and Liver Disease
Mark A. Zern, MD and Craig McClain, MD
- ❖ Pharmacological Prevention of Variceal Bleeding
Didier Lebrec, MD and Norman D. Grace, MD
- ❖ Vascular Mediators in Portal Hypertension
Roberto J. Groszmann, MD, FRC and Don C. Rockey, MD
- ❖ Steatohepatitis in Children
Joel Lavine, MD, PhD and Maureen Jonas, MD
- ❖ Autoimmune Liver Disease
Albert J. Czaja, MD and Michael P. Manns, MD
- ❖ Living Donor Liver Transplantation in the Adult*
Charles Miller, MD and Mitchell L. Shiffman, MD
- ❖ Gene Therapy for Liver Disease
Clifford J. Steer, MD and Sanjeev Gupta, MD
- ❖ Treatment of Viral Hepatitis in Children
Regino P. Gonzalez-Peralta, MD and Kathleen B. Schwarz, MD
- ❖ Hepatopulmonary Syndrome
Michael Krowka, MD and Michael B. Fallon, MD
- ❖ New Therapies for Hepatitis C
Teresa L. Wright, MD and Gary L. Davis, MD
- ❖ Genetic Factors in Gallstone Formation
Sum P. Lee, MD, PhD and David E. Cohen, MD, PhD
- ❖ Does Treatment of Hepatitis C Prevent Hepatocellular Carcinoma?

Kris V. Kowdley, MD and Massimo Colombo, MD

- ❖ Fibrogenesis: Prospects for Treatment
Scott L. Friedman, MD and Michael J. Arthur, MD
- ❖ Progress in Therapy of Wilson Disease
Michael L. Schilsky, MD and John L. Gollan, MD, PhD
- ❖ Use of TIPS in Portal Hypertension
Arun Sanyal, MD and Nathan M. Bass, MD, PhD
- ❖ Treatment of Complications of Cholestasis
Ronald J. Sokol, MD and Keith D. Lindor, MD
- ❖ Diagnostic Studies in Viral Hepatitis
Lee M. Kaplan, MD, PhD and Jack R. Wands, MD
- ❖ Hepatotoxicity of Herbal Medicines and Natural Products
Neil Kaplowitz, MD and Geoffrey C. Farrell, MD, FRACP
- ❖ The Human Genome Project and the Hepatologist
Andrea D. Branch, PhD and Paul D. Berk, MD
- ❖ Therapeutic Options in NASH
Anna Mae Diehl, MD and Arthur J. McCullough, MD

*Supported by an unrestricted educational grant from Fujisawa Healthcare, Inc.

**Supported by an unrestricted educational grant from Gilead Sciences.

Session III: Metabolic Liver Disease

1:30 p.m. - 1:50 p.m.

Hemochromatosis: Pathophysiologic Mechanisms

Bruce R. Bacon, MD

1:50 p.m. - 2:10 p.m.

Hemochromatosis: Genetic Screening and Treatment

Paul C. Adams, MD

2:10 p.m. - 2:30 p.m.

Wilson's Disease: New Insights into Copper Homeostasis and Molecular Basis of Liver Injury

Jonathan D. Gitlin, MD

2:30 p.m. - 2:50 p.m.

Advances in the Diagnosis and Treatment of Wilson's Disease
Michael L. Schilsky, MD

2:50 p.m. - 3:05 p.m.

The Elevated Serum Ferritin: What is the Diagnostic Paradigm?
Anthony S. Tavill, MD vs. Kris V. Kowdley, MD

3:05 p.m. - 3:25 p.m.

Break

3:25 p.m. - 3:45 p.m.

Hepatobiliary Disease in Cystic Fibrosis: Natural History and Management
William F. Balistreri, MD

3:45 p.m. - 4:05 p.m.

Alpha1-Antitrypsin Deficiency: Insights into Pathogenesis and Prospects for Therapy
David H. Perlmutter, MD, PhD

4:05 p.m. - 4:25 p.m.

Mitochondrial Hepatopathies: Inherited and Acquired Liver Disease
Ronald J. Sokol, MD

4:25 p.m. - 4:45 p.m.

Liver Stem Cells: Prospects for Treatment of Inherited and Acquired Liver Disease
Neil D. Theise, MD

AASLD/AHPBA Surgical Forum

Protection of the Liver in Hepatic Surgery/Cholangiocarcinoma/Living Donor Liver
Transplantation: Surgical Techniques and Decisions
Course Director: Steven M. Strasberg, MD

8:00 a.m. - 4:15 p.m.

6.5 CME Credits

Goals and Objectives

Be knowledgeable in the strategies for protection of the liver during surgery, including preoperative functional and volumetric assessments and portal vein embolization.

Be familiar with the modern diagnosis staging and treatment of hilar cholangiocarcinoma.

Be aware of recent developments in living related liver transplantation especially surgical anatomy and advanced surgical techniques.

This course is directed toward hepatobiliary surgeons, hepatologists, biliary endoscopists, gastroenterologists and interventional radiologists. The course will deal with three subjects. Dr. Myron Schwartz of Mount Sinai Hospital, New York will moderate the section on Living Donor Liver Transplantation: Surgical Techniques and Decisions. This is a rapidly evolving area of hepatic surgery and experts will discuss anatomy, techniques, regeneration and patient selection. Dr. Ted Pappas of Duke University will chair a session on Cholangiocarcinoma. This challenging cancer requires close multidisciplinary co-operation and topics will include imaging, endoscopic and surgical management, as well as radiotherapy for CCC. Dr. Pierre Clavien of the University of Zurich will lead the section covering Protection of the Liver in Hepatic Surgery. Evaluation of the cirrhotic and diseased liver, determination of minimal functional mass, protective strategies and portal vein embolization will be discussed by leading experts.

Session I: Protection of the Liver in Hepatic Surgery

Chair: Pierre A. Clavien, MD

8:00 a.m. - 8:20 a.m.

Evaluation of the Cirrhotic and Diseased Liver Prior to Surgery

Jean C. Emond, MD

8:20 a.m. - 8:40 a.m.

Evaluation of Minimal Functional Mass in Liver Surgery

Jean-Nicolas Vauthey, MD, FACS

8:40 a.m. - 9:10 a.m.

Debate Session

Portal Vein Embolization Prior to Surgery-Pro and Con

Jacques Belghiti, MD and Ravi Chari, MD

9:10 a.m. - 9:25 a.m.

Rebuttal

9:25 a.m. - 9:45 a.m.

Protective Strategies During Liver Injury
Pierre A. Clavien, MD

9:45 a.m. - 10:05 a.m.

New "Bloodless" Techniques of Liver Transection/Avoiding Inflow Occlusion
Steven M. Strasberg, MD

10:05 a.m. - 10:25 a.m.

Discussion

10:25 a.m. - 10:45 a.m.

Break

Session II: Living Donor Liver Transplantation: Why? How? Who? When?

Chair: Myron E. Schwartz, MD

10:45 a.m. - 11:05 a.m.

Applied Liver Anatomy: Lessons Learned from Living Donor Transplantation
Amadeo Marcos, MD

11:05 a.m. - 11:25 a.m.

Hepatic Regeneration in Donor and Recipient after Living Donor Transplantation
Kim M. Olthoff, MD

11:25 a.m. - 11:45 a.m.

Advanced Hepatobiliary Surgical Technique in Living Donor Transplantation
Matsutoshi Makuuchi, MD

11:45 a.m. - 12:05 p.m.

Living Donor Transplantation: When is it Better than Cadaveric? When is it Worse?
Charles Miller, MD

12:05 p.m. - 12:25 p.m.

Discussion

12:25 p.m. - 1:45 p.m.

Lunch

Session III: Hilar Cholangiocarcinoma

Chair: Theodore N. Pappas, MD

1:45 p.m. - 2:05 p.m.

Preoperative Imaging and Staging of Cholangiocarcinoma
William R. Jarnagin, MD

2:05 p.m. - 2:25 p.m.

Surgical Resection for Cholangiocarcinoma
Bryan Clary, MD

2:25 p.m. - 2:45 p.m.

Palliative Bypass for Cholangiocarcinoma
Henry A. Pitt, MD

2:45 p.m. - 3:05 p.m.

Transplantation in the Management of Cholangiocarcinoma - Screening, Diagnosis, and the Mayo Clinic Experience
Gregory J. Gores, MD

3:05 p.m. - 3:25 p.m.

Transplantation in the Management of Cholangiocarcinoma - Staging, Operative Considerations and the UCLA Experience
Ronald W. Busuttil, MD

3:25 p.m. - 3:45 p.m.

Discussion

3:45 p.m. - 4:15 p.m.

AHPBA Business Meeting (Members Only)

June 2002 NIH Management of Hepatitis C Consensus Conference

AASLD/ALF Report Back on NIH Consensus Conference on the Management of Hepatitis C

Moderators: Bruce R. Bacon, MD and Paul D. Berk, MD

5:15 p.m. – 6:15 p.m.

5:15 p.m. - 5:35 p.m.

Summary of NIH Consensus Statement
James L. Boyer, MD

5:35 p.m. - 5:55 p.m.

A comparison of 1997 and 2002 Consensus Statements
Thomas D. Boyer, MD

5:55 p.m. - 6:15 p.m.

Panel Discussion
James L. Boyer, MD
Thomas D. Boyer, MD
Jay H. Hoofnagle, MD
Leonard B. Seeff, MD
Adrian M. Di Bisceglie, MD

Registration is open to all Annual Meeting participants.

Poster Session I

5:30 p.m. - 8:00 p.m.

- ❖ Acute Liver Failure, Clinical Liver Cancer and Hepatobiliary Surgery
 - Acute Liver Failure
 - Artificial Liver Support; Hepatocyte Transplantation
 - Hepatobiliary Surgery
- ❖ Hepatic Circulation
 - Vascular Diseases and Physiology
- ❖ Liver Transplantation
 - Clinical Transplantation: Hepatitis C
 - Clinical Transplantation: Hepatitis B; other Hepatitis
 - Immunology
 - Liver Transplantation - Outcomes
 - Living Donor Transplantation
 - Experimental Transplantation
- ❖ Viral Hepatitis
 - Hepatitis C: Virology

Sunday, November 3rd, 2002

Early Morning Workshops

7:00 a.m. - 7:55 a.m.

1 CME Credit Each (3 maximum)

Basic Research Workshops

Bring together investigators in a specific area of research to discuss their ongoing work.

Focus of discussions is on new work and not a review of previous studies.

Intended for the active investigator and not for the practicing clinician.

Allow ample time for questions from the audience.

- ❖ Molecular Mechanisms of Bile Formation and Cholestasis
Nicholas F. LaRusso, MD and Sum P. Lee, MD, PhD
- ❖ Liver Regeneration
Kim M. Olthoff, MD and Linda Greenbaum, MD
- ❖ Mechanisms of Drug Induced Liver Injury
Laurie D. DeLeve, MD, PhD and Paul B. Watkins, MD
- ❖ Cytokines in Liver Disease
Anna Mae Diehl, MD and Bin Gao, MD, PhD
- ❖ Molecular Virology of Hepatitis C
David R. Gretch, MD, PhD and Andrea D. Branch, PhD
- ❖ New Immunosuppressive Drugs
Gary A. Levy, MD, FRCP(C) and Russell H. Wiesner, MD
- ❖ Genetics of Wilson's Disease
Eve A. Roberts, MD, FRCPC and John L. Gollan, MD, PhD
- ❖ Pathogenesis of Alcoholic Liver Disease
Samuel W. French, MD, RCPS (C) and Amin A. Nanji, MD, FRCP

Clinical Management Workshops

Discuss difficult management issues utilizing acknowledged experts in the

area.

Provide an overview of the current state-of-the-art in each area.

Intended for the clinician who is seeking the most updated information on a difficult area of management.

Allow ample time for questions from the audience.

- ❖ Treatment of Hepatitis C Following Liver Transplant
Mitchell L. Shiffman, MD and Jorge L. Rakela, MD
- ❖ Treatment of Hepatitis C in the Patient with Hypersplenism and Cirrhosis
Vinod K. Rustgi, MD and John G. McHutchison, MD
- ❖ Treatment of Hepatocellular Carcinoma
Andreas G. Tzakis, MD and K. Rajender Reddy, MD
- ❖ Living Donor Transplantation - Risks and Benefits*
Robert A. Fisher, MD, FACS and Robert S. Brown, Jr., MD, MPH
- ❖ NASH (clinical aspects)
Naga P. Chalasani, MD and Brent A. Tetri, MD
- ❖ Management of Esophageal and Gastric Varices
J. Michael Henderson, MD and Guadalupe Garcia-Tsao, MD
- ❖ Screening for Hepatocellular Carcinoma
Brian J. McMahon, MD and Morris Sherman, MD, PhD
- ❖ Screening for Hemochromatosis
Kris V. Kowdley, MD and Paul C. Adams, MD

*Supported by an unrestricted educational grant from Fujisawa Healthcare, Inc.

Plenary and Parallel Session

8:00 a.m. - 9:30 a.m.

Liver Transplantation Plenary I

10:30 a.m. - 12:00 p.m.

Hepatic Surgery and Experimental Transplantation Plenary II

3:00 p.m. - 4:30 p.m.

Parallel Session I: Cell Biology

Parallel Session II :HCV Virology
Parallel Session III :Liver Surgery: Experimental
Parallel Session IV: NASH and Alcoholic Liver Disease: Experimental
Parallel Session V: Organic Anion and Bile Acid Transport
Parallel Session VI: Pediatric Transplantation
Parallel Session VII: Viral Hepatitis Following Liver Transplantation

4:45 p.m. - 6:15 p.m.

Parallel Session VIII: Advances and Controversies in the Practice of Clinical Hepatology
Parallel Session IX: Cholangiocyte: Cell Biology and Transport
Parallel Session X: Gene Expression and Therapy
Parallel Session XI: Hepatitis C: Pathogenesis and Immunity
Parallel Session XII: Liver Transplant Outcomes
Parallel Session XIII: Portal Hypertension: Pathogenesis
Parallel Session XIV: Viral Hepatitis and HIV

Research Workshop

Nitric Oxide (NO) and the Liver

Course Director: Don C. Rockey, MD

Sunday, November 3, 2002

8:00 a.m. - 3:30 p.m.

7.5 CME Credits

Goals and Objectives:

Highlight important aspects of NO biology to AASLD research attendees not working in the NO field and by doing so, lead to the genesis of new areas of research by active members.

Introduce NO investigators to important aspects of liver biology.

Generate interest by junior investigators in the area of NO and liver biology.

Introduce multiple aspects of NO biology to non-investigative AASLD attendees.

Nitric oxide (NO), is a free radical that signals by chemical reaction with protein targets, and has been implicated in a wide range of biological functions. NO was discovered to be a potent vasodilator, inhibitor of platelet aggregation, and active species of nitroglycerin before the discovery of endothelium-derived relaxing factor (EDRF) in 1980. Multiple advances over the past two decades, and in particular a

heightened focus on NO in the 1990's has led to a better understanding of the role of NO in health and disease. Recognition of the importance of NO led to the awarding of the Nobel Prize in Medicine in 1998 to its co-discoverers.

**Enzymology, Biochemistry, and Basic Cell Biologic Aspects of Nitric Oxide
Chair: Don C. Rockey, MD**

8:00 a.m. - 8:05 a.m.

Introduction and Welcome
Don C. Rockey, MD

8:05 a.m. - 8:35 a.m.

Biological Reactions Involving Nitric Oxide
Jonathan Stamler, MD

8:40 a.m. - 9:10 a.m.

Biochemistry of Nitric Oxide Synthesis
Dennis Stuehr, PhD

9:15 a.m. - 9:45 a.m.

Oxidant-Dependent Mechanisms for Modulating Nitric Oxide Signaling
Jason Eiserich, PhD

9:50 a.m. - 10:20 a.m.

Endothelial Cell Derived Nitric Oxide
Thomas Michel, MD, PhD, FACC

10:25 a.m. - 10:45 a.m.

Break

**Hepatotoxicity, Injury and Nitric Oxide
Chair: Don C. Rockey, MD**

10:45 a.m. - 11:05 a.m.

Nitric Oxide, the Liver and Apoptosis
Timothy M. Billiar, MD

11:15 a.m. - 11:35 a.m.

Nitric Oxide and Liver Regeneration
Anna Mae Diehl, MD

11:45 a.m. - 12:05 p.m.

Ethanol Induced Injury and Nitric Oxide
Gavin E. Arteel, PhD

12:15 p.m. - 1:30 p.m.

Lunch and Poster Viewing

Hepatic Blood Flow and Nitric Oxide
Chair: Vijay Shah, MD

1:30 p.m. - 1:50 p.m.

The Role of Nitric Oxide in Hepatic Venous-Occlusive Disease
Laurie D. DeLeve, MD, PhD

2:00 p.m. - 2:20 p.m.

Nitric Oxide Mediated Regulation of Sinusoidal Blood Flow
Mark G. Clemens, PhD

2:30 p.m. - 2:50 p.m.

Ischemia-Reperfusion Injury and Nitric Oxide
Matthew B. Grisham, PhD

3:00 p.m. - 3:20 p.m.

Nitric Oxide, Hepatic Fibrosis and Portal Hypertension
Stefano Fiorucci, MD

3:30 p.m.

Adjourn

New Symposia for 2002 - General Hepatology Update

Moderators: Kenneth D. Flora, MD and David S. Raiford, MD

3:00 p.m. - 4:30 p.m.

1.5 CME Credits

Goals and Objectives

Become more familiar with the latest in hepatitis B therapy.

Understand how the use of MELD scores should alter referral practices for liver transplantation.

Understand the latest strategies in the management of ascites.

This session should be of particular interest to the practicing hepatologist. Attendees will hear about the latest developments on topics summarized by leading authorities in their specialty area. Presentations will be made in symposium format with a question period following each talk.

3:00 p.m. - 3:30p.m.

Current Therapy in Hepatitis B
Robert P. Perrillo, MD

3:30 p.m. - 4:00 p.m.

Management of Ascites
Arun Sanyal, MD

4:00 p.m. - 4:30 p.m.

Liver Transplant Referrals in the Era of MELD
Jeffrey S. Crippin, MD

4:45p.m. - 6:15 p.m.

Advances and Controversies in the Clinical Practice of Hepatology. This peer-reviewed abstract session has been designed to complement the Update.

State-of-the-Art Lectures

9:30 a.m. - 10:00 a.m.

Transplant Surgery State-of-the-Art Lecture
New Immunosuppressive Agents
Gary A. Levy, MD, FRCP(C)

12:00 p.m. - 12:30 p.m.

Sheila Sherlock State-of-the-Art Lecture
Primary Biliary Cirrhosis
E. Jenny Heathcote, MD

Hepatology Associates Course

8:00 a.m. - 4:30 p.m.

7.5 Contact Hours

Course Directors: Carla Viscomi, RN, BSN and Mary Ellen Geraghty, RN, BSN, CGRN

Goals and Objectives:

Explain HIPAA and how, as researchers, we need to follow it to protect clinical research subjects.

Teach the clinical manifestations, pathogenesis, and treatment of liver disease associated with alpha1-antitrypsin deficiency.

Prepare tactics for HCV therapy and hepatitis C therapy non-compliance due to side effects.

This one-day program is designed specifically for the hepatology associate (nurse, physician assistant, research or transplant coordinator, or other hepatology health professional) interested in expanding their knowledge base for the treatment of patients with liver disease. This course will elaborate on diagnosis, pathogenesis, side effects and treatments involving HCV, interferon, ribiflavin, Wilson's disease, chronic hepatitis C, alpha1-antitrypsin, and other various liver diseases. Participants must have paid tuition fee, signed in, attended the entire course, completed an evaluation, and signed out, in order to receive a certificate of completion/attendance. Participants not fulfilling these requirements will not receive a certificate. Failure to sign in or out will result in forfeiture of credit for the entire course. No exceptions will be made. Partial credit is not available. Certificates will be sent after the course.

8:00 a.m. - 8:45 a.m.

Clinical Aspects of Alpha* - Antitrypsin
David H. Perlmutter, MD, PhD

8:45 a.m. - 9:30 a.m.

Protecting the Rights of Clinical Research
Tiffany Geaghan, PA-C and
Katherine Wherity, RN, BSN

9:30 a.m. - 9:45 a.m.

Break

9:45 a.m. - 10:30 a.m.

Adherence in the Management of HCV Therapy
Karen K. Luken, RN, ARNP

10:30 a.m. - 11:00 a.m.

Alcoholic Liver Disease
Arthur J. McCullough, MD

11:00 a.m. - 11:45 a.m.

Grading and Staging of Liver Diseases in Adults and Children
Jay H. Lefkowitz, MD

11:45 a.m. - 1:15 p.m.

Lunch

1:15 p.m. - 1:30 p.m.

Business Meeting

1:30 p.m. - 2:15 p.m.

Psychological Aspects of Hepatitis C
Paul Kwo, MD

2:15 p.m. - 2:45 p.m.

Wilson's Disease in Children
Michael L. Schilsky, MD

2:45 p.m. - 3:00 p.m.

Break

3:00 p.m. - 3:45 p.m.

Fatty Liver Disease in Childhood
Robert H. Squires, MD

3:45 p.m. - 4:30 p.m.

Biliary Abnormalities in the Newborn
Ronald J. Sokol, MD

*Supported, in part, by an unrestricted educational grant from Schering Hepatitis Innovations.

Poster Session II

Viewing Time: 8:00 a.m. - 5:00 p.m.

Presentation Time: Even #s 12:30 p.m. - 1:45 p.m. Odd #s 1:45 p.m. - 3:00 p.m.

- ❖ Cellular and Molecular Biology
 - Cell Biology
 - Gene Expression and Therapy
 - Cell Proliferation and Carcinogenesis

- ❖ Fibrogenesis
 - Liver Fibrosis

- ❖ Viral Hepatitis
 - Hepatitis C: Pathogenesis and Immunology
 - Hepatitis C: Mechanisms and Other Treatment Issues

Monday, November 4th, 2002

Early Morning Workshops

7:00 a.m. - 7:55 a.m.

1 CME Credit Each (3 maximum)

Basic Research Workshops

Bring together investigators in a specific area of research to discuss their ongoing work.

Focus of discussions is on new work and not a review of previous studies.

Intended for the active investigator and not for the practicing clinician.

Allow ample time for questions from the audience.

- ❖ Apoptosis and Hepatocellular Necrosis
Greg J. Gores, MD and Mark J. Czaja, MD

- ❖ Pathogenesis of the Hyperdynamic Circulation of Cirrhosis
Vijay Shah, MD and Roberto J. Groszmann, MD, FRC

- ❖ Cholangiocyte Cell Biology
Nicholas F. LaRusso, MD and Alphonse Sirica, MS, PhD

- ❖ Pathogenesis of NASH

Arun Sanyal, MD and Geoffrey C. Farrell, MD, FRACP

- ❖ Pathogenesis of PBC and PSC
John M. Vierling, MD and Eric M. Gershwin, MD
- ❖ Hepatic Fibrosis
David A. Brenner, MD and Michael J. Arthur, MD
- ❖ Molecular Virology of Hepatitis B
Timothy Block, MD and Kyong-Mi Chang, MD

Clinical Management Workshops

Discuss difficult management issues utilizing acknowledged experts in the area.

Provide an overview of the current state-of-the-art in each area.

Intended for the clinician who is seeking the most updated information on a difficult area of management.

Allow ample time for questions from the audience.

- ❖ Complimentary and Alternative Medicine in Liver Disease
Leonard B. Seeff, MD and Thomas Kresina, MD, PhD
- ❖ Diagnosis and Management of Hemochromatosis
Bruce R. Bacon, MD and Herbert L. Bonkovsky, MD
- ❖ Hepatopulmonary Syndrome
Michael B. Fallon, MD and Michael Krowka, MD
- ❖ Therapy of Hepatitis B
Anna S.F. Lok, MD and Robert P. Perrillo, MD
- ❖ Ascites and Spontaneous Bacterial Peritonitis
Bruce A. Runyon, MD and Douglas R. LaBrecque, MD
- ❖ Neonatal Cholestatic Disorders
Ronald J. Sokol, MD and William F. Balistreri, MD
- ❖ Nutritional Therapy in Liver Disease
Stephen J. O'Keefe, MD and Arthur J. McCullough, MD
- ❖ Treatment of Alcoholic Hepatitis
Charles S. Lieber, MD and Timothy R. Morgan, MD

Plenary and Parallel Session

8:00 a.m. - 9:30 a.m.

Presidential Plenary I

11:00 a.m. - 12:30 p.m.

Presidential Plenary II

3:00 p.m. - 4:30 p.m.

Parallel Session XV: Bile Acid and Cholesterol Metabolism

Parallel Session XVI: Cell Death and Cytoprotection

Parallel Session XVII: Hepatitis B: Treatment

Parallel Session XVIII: Hepatocellular Carcinoma: Diagnosis and Natural History

Parallel Session XIX: HCV: Novel Therapeutic Approaches

Parallel Session XX: Living Donor Liver Transplantation

Parallel Session XXI: Metabolic and Genetic Diseases

4:45 p.m. - 6:15 p.m.

Parallel Session XXII: Cell Proliferation and Carcinogenesis

Parallel Session XXIII: Genetic Cholestatic Disease

Parallel Session XXIV: HCV Treatment

Parallel Session XXV: Hepatitis B: Pathogenesis

Parallel Session XXVI: Hepatitis C: Progression of Fibrosis

Parallel Session XXVII: Liver Fibrogenesis and Stellate Cell Biology

Parallel Session XXVIII: Portal Hypertension: Clinical and Experimental

State-of-the-Art Lecture

10:00a.m. – 10:30a.m.

Hans Popper Basic Science Research State-of-the-Art Lecture

Biology of Liver Development

Kenneth S. Zaret, PhD

Poster Session III

Viewing Time: 8:00 a.m. - 5:00 p.m.

Presentation Time: Even #s 12:30 p.m. - 1:45 p.m. Odd #s 1:45 p.m. - 3:00 p.m.

- ❖ Complications of Cirrhosis
- ❖ Hepatotoxicity and Cell Death
- ❖ Metabolic and Genetic Disease

- ❖ Transport and Biliary Physiology
 - Bile Acids/Cholesterol/Bilirubin in Metabolism
 - Transport and Biliary Physiology
 - Cholangiocyte Biology
- ❖ Viral Hepatitis
 - Hepatitis C: Diagnosis and Natural History
 - Hepatitis C Treatment
 - Hepatitis B: Pathogenesis and Diagnosis
 - Hepatitis B: Treatment
 - Other Viral Hepatitis
- ❖ Public Policy, Epidemiology and Decision Analysis

Tuesday, November 5th, 2002

Early Morning Workshops

Basic Research Workshops

Bring together investigators in a specific area of research to discuss their ongoing work.

Focus of discussions is on new work and not a review of previous studies.

Intended for the active investigator and not for the practicing clinician.

Allow ample time for questions from the audience.

- ❖ Role of Oxidant Stress in Drug Induced Liver Disease
Hartmut Jaeschke, PhD and John J. LeMasters, MD, PhD
- ❖ Molecular Defects in Cholestasis
Gerald Salen, MD and Frederick Suchy, MD
- ❖ Hepatic Stem Cells
David A. Shafritz, MD and Sanjeev Gupta, MD
- ❖ Alpha1-Antitrypsin Deficiency and Diseases of Protein Misfolding
Jeffrey Teckman, MD
- ❖ Pathogenesis of Autoimmune Hepatitis
Edward L. Krawitt, MD and Michael P. Manns, MD
- ❖ Organic Anion and Bile Acid Transport
Paul A. Dawson, PhD and Peter J. Meier-Abt, MD

- ❖ Pathogenesis of Gallstones
Douglas M. Heuman, MD and Martin C. Carey, MD, DSC

Clinical Management Workshops

Discuss difficult management issues utilizing acknowledged experts in the area.

Provide an overview of the current state-of-the-art in each area.

Intended for the clinician who is seeking the most updated information on a difficult area of management.

Allow ample time for questions from the audience.

- ❖ Treatment of NASH
Brent A. Tetri, MD and Stephen H. Caldwell, MD
- ❖ Treatment of Hepatitis C in Hemophiliacs and Dialysis Patients
Richard K. Sterling, MD and Michael W. Fried, MD
- ❖ Treatment of Hepatitis C in Children
Maureen Jonas, MD and Rene Romero, MD
- ❖ Treatment of Autoimmune Hepatitis
E. Jenny Heathcote, MD and Robert L. Carithers, Jr., MD
- ❖ Management of VOD and Budd-Chiari Syndrome
George B. McDonald, MD and Dominique Valla, MD
- ❖ Role of TIPS in the Management of Patients with Portal Hypertension
Patrick S. Kamath, MD and Nathan M. Bass, MD, PhD
- ❖ Use of PEG vs Interferon - What are the Differences
Karen L. Lindsay, MD and Nezam Afdhal, MD

Plenary and Parallel Session

8:00 a.m. - 9:30 a.m.

Presidential Plenary III

11:15 a.m. - 12:45 p.m.

Parallel Session XXIX: Acute Liver Failure

Parallel Session XXX: Fatty Liver and Alcoholic Disease; Clinical Features and Treatment

Parallel Session XXXI: HCV Treatment: Mechanisms of Response/Non-Response

Breakthrough

Parallel Session XXXII: Hepatitis C: Factors Affecting Diagnosis and Natural History

Parallel Session XXXIII: Hepatocellular Carcinoma: Experimental Approaches to Therapy

Parallel Session XXXIV: Primary Biliary Cirrhosis

State-of-the-Art Lecture

9:30 a.m. - 10:00 a.m.

Leon Schiff State-of-the-Art Lecture

Old and New Hepatitis Vaccines

Robert H. Purcell, MD

Poster Session IV

Viewing Time: 8:00 a.m. - 12:30 p.m.

Presentation Time: 10:00 a.m. - 11:15 a.m.

- ❖ Acute Liver Failure, Clinical Liver Cancer and Hepatobiliary Surgery
- ❖ Hepatocellular Carcinoma and Other Liver Malignancies
- ❖ Fatty Liver Disease
 - Alcoholic Liver Disease - Experimental
 - NASH - Experimental
 - ASH and NASH - Clinical
 - Other Fatty Liver Diseases - Clinical and Experimental
- ❖ Biliary Tract and Immunologic Liver Disease
 - Cholestatic and Autoimmune Liver Diseases

A service brought to you by the Hepatitis C Support Project HCV Advocate
www.hcvadvocate.org